Astra Nova Training and ACRES announced a strategic alliance collaboration
Astra Nova Training, a global provider of consultancy and pharma training services, and the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit integrating the expertise and investments of research stakeholders world-wide to build and maintain a global system for clinical trials, announced a strategic alliance collaboration to improve the expertise of industry professionals through improved and easily available training quality.
UK-based Astra Nova has introduced an international network of over 140 industry experts, as well as over 20 free and commercial online training courses, accessible on their Learning Management System. More than 5,000 professionals worldwide have obtained industry certification through their in-house and online training solutions. Astra Nova, with a strong commitment to corporate social responsibility, will make available interactive and easy-to access online training solutions for ACRES Global Platform of services.
With Astra Nova, ACRES will provide timely information on critical training topics and materials needed globally and they will partner on Learning Management Systems development. Other collaborative efforts involve jointly organizing multi-stakeholder events dedicated to improving the conduct of clinical research globally.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.